FIELD: biotech.
SUBSTANCE: invention relates to the field of biotechnology. The present invention discloses nucleic acid molecules containing one or more nucleic acid sequences that encode a mutated PRAME consensus antigen. Disclosed are vectors, compositions and vaccines containing one or more nucleic acid sequences that encode a mutated PRAME consensus antigen. Methods of treating a subject with a PRAME-expressing tumor and methods of preventing a PRAME-expressing tumor are disclosed. A mutated PRAME consensus antigen is disclosed.
EFFECT: methods of treating a PRAME-expressing tumor disclosed.
41 cl, 19 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SURVIVIN-TARGETED ANTI-CANCER VACCINES AND APPLICATIONS THEREOF | 2018 |
|
RU2776949C2 |
| ANTI-CANCER VACCINES TARGETED WITH SURVIVIN AND THEIR APPLICATION | 2018 |
|
RU2751253C1 |
| ANTICANCER VACCINES TARGETING BORIS AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2759681C1 |
| BORIS-TARGETED ANTI-CANCER VACCINES AND METHODS FOR APPLICATION THEREOF | 2018 |
|
RU2799786C2 |
| ANTI-CANCER VACCINES AIMED AT LEMD1 AND THEIR USE | 2018 |
|
RU2760984C1 |
| MESOTHELIN-TARGETED CANCER VACCINES AND THEIR APPLICATIONS | 2018 |
|
RU2830879C2 |
| MESOTHELINE-TARGETED CANCER VACCINES AND THEIR APPLICATION | 2018 |
|
RU2751252C1 |
| MUC16-TARGETING ANTICANCER VACCINES AND APPLICATION THEREOF | 2018 |
|
RU2777918C2 |
| ANTI-CANCER VACCINES TARGETING MUC16 AND THEIR USE | 2018 |
|
RU2750689C1 |
| THERAPY FOR TREATING CANCER BY INTRATUMORAL AND/OR INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA CODING 4-1BBL (CD137L) AND/OR CD40L | 2019 |
|
RU2830601C2 |
